Video

Dr. Pinato on Guidelines for Toxicity Management in HCC

David J. Pinato, MD, discusses guidelines for toxicity management in hepatocellular carcinoma (HCC).

David J. Pinato, MD, clinician scientist, consultant medical oncologist, Department of Surgery and Cancer, Imperial College of London, discusses guidelines for toxicity management in hepatocellular carcinoma (HCC). 

Although papers have been published on the characteristics of toxicities in HCC, the guidelines set forth by the American Society of Clinical Oncology, the European Society for Medical Oncology, and the Society for Immunotherapy of Cancer offer reliable sources of guidance for toxicity evaluation, Pinato explains. These guidelines include information on diagnosingimmune pathology in the context of checkpoint inhibitors, as well as maintaining broad differentials when a patient develops toxicity, Pinato says. 

It is important to take these differentials into consideration so that the cause of the toxicity can be correctly identified and the treatment can be tailored based on adverse effect ​severity, Pinato continues. Understanding this can ensure patients are not over or undertreated, Pinato concludes.

Related Videos
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on tremelimumab/durvalumab vs atezolizumab/bevacizumab in unresectable HCC.